Gastric Adenocarcinoma — Trials

Gastric Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

447 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 137
Recruiting: 69
Ph III recruiting: 12
Growth YoY: +31.3%
Industry share: 22%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 31.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 51–100 of 447 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03641313	Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	active not recruiting	Phase 2	17	National Cancer Institute (NCI)NIH	1	Jul 30, 2026	clinicaltrials
NCT06914687	Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma	active not recruiting	Phase 2	30	Fudan UniversityOTHER	1	Jul 28, 2026